𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entacapone and selegiline with l-dopa in patients with Parkinson's disease: an interaction study

✍ Scribed by J Lyytinen; S Kaakkola; A Gordin; E.-R Kultalahti; H Teräväinen

Book ID
117751664
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
160 KB
Volume
6
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dementia and treatment with L-dopa in Pa
Dementia and treatment with L-dopa in Parkinson's disease
✍ M. Hietanen; Dr. H. Teräväinen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L-dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who w

Idazoxan, an alpha-2 antagonist, and L-D
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
✍ O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. T 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induc